Faisal Khurshid
Stock Analyst at Leerink Partners
(0.71)
# 3,773
Out of 4,843 analysts
19
Total ratings
28.57%
Success rate
-17.97%
Average return
Main Sectors:
Stocks Rated by Faisal Khurshid
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRWD Ironwood Pharmaceuticals | Maintains: Market Perform | $3 → $1 | $0.60 | +66.92% | 2 | Apr 14, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | $45 | $15.27 | +194.70% | 1 | Apr 8, 2025 | |
| NRIX Nurix Therapeutics | Initiates: Market Perform | $16 | $10.63 | +50.52% | 1 | Mar 17, 2025 | |
| STTK Shattuck Labs | Initiates: Outperform | $4 | $1.01 | +296.04% | 1 | Mar 17, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Market Perform | $33 → $2 | $1.35 | +48.15% | 2 | Mar 3, 2025 | |
| ATYR aTyr Pharma | Initiates: Outperform | $16 | $4.47 | +257.94% | 1 | Feb 18, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $60 | $29.64 | +102.43% | 2 | Dec 27, 2024 | |
| ANIP ANI Pharmaceuticals | Initiates: Outperform | $80 | $58.72 | +36.24% | 1 | Dec 11, 2024 | |
| ZURA Zura Bio | Initiates: Outperform | $15 | $1.01 | +1,385.15% | 1 | Nov 4, 2024 | |
| TRVI Trevi Therapeutics | Assumes: Outperform | $7 | $6.51 | +7.53% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $45 | $18.46 | +143.77% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $24 | $28.73 | -16.46% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.52 | +360.53% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $4.15 | +92.77% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $5 | $0.66 | +657.69% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $11 | $3.60 | +205.22% | 1 | Mar 21, 2023 |
Ironwood Pharmaceuticals
Apr 14, 2025
Maintains: Market Perform
Price Target: $3 → $1
Current: $0.60
Upside: +66.92%
Spyre Therapeutics
Apr 8, 2025
Initiates: Outperform
Price Target: $45
Current: $15.27
Upside: +194.70%
Nurix Therapeutics
Mar 17, 2025
Initiates: Market Perform
Price Target: $16
Current: $10.63
Upside: +50.52%
Shattuck Labs
Mar 17, 2025
Initiates: Outperform
Price Target: $4
Current: $1.01
Upside: +296.04%
Pliant Therapeutics
Mar 3, 2025
Downgrades: Market Perform
Price Target: $33 → $2
Current: $1.35
Upside: +48.15%
aTyr Pharma
Feb 18, 2025
Initiates: Outperform
Price Target: $16
Current: $4.47
Upside: +257.94%
Kymera Therapeutics
Dec 27, 2024
Maintains: Outperform
Price Target: $60
Current: $29.64
Upside: +102.43%
ANI Pharmaceuticals
Dec 11, 2024
Initiates: Outperform
Price Target: $80
Current: $58.72
Upside: +36.24%
Zura Bio
Nov 4, 2024
Initiates: Outperform
Price Target: $15
Current: $1.01
Upside: +1,385.15%
Trevi Therapeutics
Sep 9, 2024
Assumes: Outperform
Price Target: $7
Current: $6.51
Upside: +7.53%
Sep 9, 2024
Assumes: Outperform
Price Target: $45
Current: $18.46
Upside: +143.77%
Sep 9, 2024
Initiates: Market Perform
Price Target: $24
Current: $28.73
Upside: -16.46%
Sep 9, 2024
Initiates: Outperform
Price Target: $7
Current: $1.52
Upside: +360.53%
Sep 9, 2024
Assumes: Outperform
Price Target: $8
Current: $4.15
Upside: +92.77%
Sep 9, 2024
Assumes: Outperform
Price Target: $5
Current: $0.66
Upside: +657.69%
Mar 21, 2023
Initiates: Outperform
Price Target: $11
Current: $3.60
Upside: +205.22%